Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
NCT00050960
Completed
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2012
Locations: Drs. Carroll, Sheth, and Raghavan, Louisville, Kentucky
Conditions: Non-small Cell Lung Cancer
Register for Updates
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
NCT00003127
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic, recurrent, or refractory endometrial cancer.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
06/13/2012
Locations: Veterans Affairs Medical Center - Lexington, Lexington, Kentucky +1 locations
Conditions: Endometrial Cancer
Register for Updates
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
NCT00102973
Completed
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2012
Locations: James Graham Brown Cancer Center, Louisville, Kentucky +1 locations
Conditions: Ovarian Neoplasms
Register for Updates
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
NCT00343291
Completed
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
NCT00113516
Completed
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2010
Locations: Pfizer Investigational Site, Louisville, Kentucky +3 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
NCT00097214
Completed
This is a phase II study in previously untreated subjects with histologically or cytologically proven stage IIIB/IV NSCLC designed to determine the efficacy of first line treatment with carboplatin and cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Louisville, Kentucky
Conditions: Non-small Cell Lung Cancer
Register for Updates
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
NCT00097227
Completed
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Louisville, Kentucky
Conditions: Non-small Cell Lung Cancer
Register for Updates
Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
NCT00264134
Terminated
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2010
Locations: Kentuckiana Cancer Institute, Louisville, Kentucky
Conditions: Non-small Cell Lung Cancer, Extensive Stage Unresectable
Register for Updates
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
NCT00363415
Completed
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/20/2009
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky +1 locations
Conditions: Small Cell Lung Cancer
Register for Updates
CPG 7909 Injection in Non-Small Cell Lung Cancer
NCT00070629
Completed
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every ot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2009
Locations: Kentucky Cancer Clinic, Hazard, Kentucky
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00069901
Completed
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2008
Locations: University of Louisville, Louisville, Kentucky
Conditions: Ovarian Neoplasm
Register for Updates
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
NCT00174356
Completed
The main purpose of this study is to evaluate the overall safety and maximum dose of CI 1033 in combination with paclitaxel and carboplatin in patients with NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2006
Locations: Pfizer Investigational Site, Louisville, Kentucky +1 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates